Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$140.80 USD
+3.76 (2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $140.63 -0.17 (-0.12%) 6:36 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 281 - 300 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Corporate Update: Remaining 2017 Catalysts Include Pipeline Progress, Potential for a TransCon Deal and Long-Acting hGH Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
ENDO: Eight Pipeline Presentations Provide Plenty of Exposure for Endocrinologists; Reiterate OUTPERFORM and $34 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY16 Financials; Pipeline Progress on Multiple Fronts; Reiterate OUTPERFORM and Raising PT to $34 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY16 Financials; Pipeline Progress on Multiple Fronts; Reiterate OUTPERFORM and Raising PT to $34 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Pediatric and Adult GHD Publications Validate TC-hGH Phase 2 Results in Our View; Reiterate OUTPERFORM and $31 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Key Opinion Leader Views TC-hGH as a Top Candidate for Long-Acting hGH; Reiterate OUTPERFORM and $31 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3 Update; Pivotal Trial for TransCon hGH on Track with Enrollment Initiated; Reiterate OUTPERFORM and $31 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3 Update; Pivotal Trial for TransCon hGH on Track with Enrollment Initiated; Reiterate OUTPERFORM and $31 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Financing Covers Pivotal Data Readout for TransCon hGH; Reiterate OUTPERFORM but Reducing Price Target to $31 (from $34) for Dilution
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L